TMCnet News

Research and Markets: Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines
[June 18, 2013]

Research and Markets: Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/gxgxnv/triple_analysis) has announced the addition of the "Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines" report to their offering.

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer

The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.

Part II: Angiogenesis


The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.

Part III: Cancer Vaccines

The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty.

For more information visit http://www.researchandmarkets.com/research/gxgxnv/triple_analysis

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To TMCnet.com's Homepage ]